February 7, 2024
Eisai Global Alzheimer’s Disease Oficer Keisuke Naito Eisai revealed on February 6 that 2,000 patients are currently receiving treatment with its Alzheimer’s drug Leqembi (lecanemab) in the US, with some four times this number on a waiting list. “We expect...read more